Related Experiment Videos
Faster cholinergic REM sleep induction in euthymic patients with primary affective illness
Science (New York, N.Y.)
|April 11, 1980
Summary
Patients with primary affective illness show a faster onset of rapid eye movement sleep when given arecoline, a cholinergic agonist. This suggests a potentially supersensitive cholinergic system in these patients, even during remission.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Cholinergic system involvement in affective disorders is increasingly recognized.
- Primary affective illness (e.g., depression, bipolar disorder) is associated with various neurobiological alterations.
Purpose of the Study:
- To investigate the cholinergic system's sensitivity in patients with primary affective illness during remission.
- To compare the effects of a cholinergic agonist on sleep onset in patients versus healthy controls.
Main Methods:
- Administered arecoline, a muscarinic receptor agonist, to patients with primary affective illness in remission and age/sex-matched healthy controls.
- Monitored and compared the latency to rapid eye movement (REM) sleep onset between groups.
Main Results:
- Arecoline significantly shortened the latency to REM sleep in patients with primary affective illness compared to controls.
- This effect was observed even when participants were in clinical remission.
Conclusions:
- Patients with primary affective illness may possess a supersensitive cholinergic system.
- This cholinergic supersensitivity might persist even in the absence of overt clinical symptoms.
- Findings suggest a potential neurobiological marker for primary affective illness.